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Abstract
Purpose—Approximately 30%higher-grade premalignant oral intraepithelial neoplasia (OIN)
lesions will progress to oral cancer. While surgery is the OIN treatment mainstay, many OIN
lesions recur which is highly problematic for both surgeons and patients. This clinical trial
assessed the chemopreventive efficacy of a natural-product based bioadhesive gel on OIN lesions.
Experimental Design—This placebo-controlled multicenter study investigated the effects of
topical application of bioadhesive gels that contained either 10% w/w freeze dried black
raspberries (BRB) or an identical formulation devoid of BRB placebo to biopsy-confirmed OIN
lesions (0.5 gm × q.i.d., 12 weeks). Baseline evaluative parameters (size, histologic grade, LOH
events) were comparable in the randomly assigned BRB (n=22) and placebo (n=18) gel cohorts.
Evaluative parameters were: histologic grade, clinical size and loss of heterozygosity (LOH).
Results—Topical application of the BRB gel to OIN lesions resulted in statistically significant
reductions in lesional sizes, histologic grades and LOH events. In contrast, placebo gel lesions
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demonstrated a significant increase in lesional size and no significant effects on histologic grade
or LOH events. Collectively, these data strongly support BRB’s chemopreventive impact. A
cohort of very BRB-responsive patients-as demonstrated by high therapeutic efficacy-was
identified. Corresponding protein profiling studies, which demonstrated higher pretreatment levels
of BRB metabolic and keratinocyte differentiation enzymes in BRB-responsive lesions, reinforce
the importance of local metabolism and differentiation competency.
Conclusions—Results from this trial substantiate the LOH reductions identified in the pilot
BRB gel study and extend therapeutic effects to significant improvements in histologic grade and
lesional size.
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Introduction
Oral squamous cell carcinoma (OSCC) is a world-wide health problem and one of the most
challenging-to-treat human malignancies (1). This is due to the insidious nature of its early
disease, reliance upon surgery as the primary treatment modality, and the difficulty of
achieving loco-regional disease control (1, 2). Many OSCC patients die from massive local
recurrence or second primary tumors (3, 4). Also, despite treatment innovations like
inductive chemotherapy and radiation intensification programs, OSCC survival rates remain
among the lowest for solid tumors (4, 5). Those patients fortunate enough to be cured often
encounter major esthetic and functional issues with their face and mouth (6).
OSCCs arise from malignant progression of a recognized precursor surface epithelial lesion
i.e. oral intraepithelial neoplasia (OIN). While not all premalignant lesions transform, over
30% of the higher grade (moderate to severe) OIN lesions progress to OSCC (7, 8).
Furthermore, many OIN lesions recur despite obtaining microscopically clear surgical
margins; which is frustrating for both clinician and patient and mandates close follow up and
additional biopsies (9). Such OIN recurrences imply persistent mutations in the epithelial
stem cells responsible for post-biopsy wound repair and re-enforce the need for novel
treatment strategies beyond surgery or laser ablation (9). Identification of effective, non-
toxic chemopreventive strategies to induce OIN regression, prevent OIN recurrence or
suppress progression to OSCC emerges as an appealing approach for long term OIN
management.
Previous OSCC prevention trials have employed a variety of chemopreventive compounds
including retinoic acid and its derivatives (10), green tea and associated polyphenols (11),
and the COX-2 inhibitor, Celecoxib (12), as well as combination of Celecoxib and the
EGFR inhibitor Erlotinib (13). Unfortunately, the majority of these previous studies, which
relied on systemic agent administration, resulted in modest to negligible chemopreventive
effects (10–12) and induced appreciable toxicities (13).
BRB were selected as the trial chemopreventive due to their success in our previous in vitro
and in vivo chemoprevention studies (14, 15) and because of their chemopreventive-rich
composition which includes four anthocyanins [the predominant BRB polyphenols which
provide appreciable chemopreventive impact (16)], ellagic acid, ferulic acid, coumaric acid,
and quercetin, phytosterols in addition to folic acid and selenium (17, 18). Furthermore,
local BRB anthocyanin metabolism has the potential to sustain local chemopreventive
effects e.g. deglycosylation generates highly active anthocyanidins which subsequently are
converted to a more stable chemopreventive i.e. protocatechuic acid that can undergo local
enteric recycling (19).
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Our pilot clinical trial results showed topical application of a bioadhesive gel that contained
10% w/w freeze dried black raspberries (BRB, 0.5 gm, q.i.d. for 6 weeks, n=20)
significantly reduced loss of heterozygosity (LOH) in OIN lesions, modulated epithelial
gene expression towards terminal epithelial differentiation, and significantly reduced OIN
levels of COX-2 (14, 15). These pilot trial data also revealed appreciable inter-patient
variations in BRB gel responsiveness (14, 15). A subsequent study was conducted to
characterize intra oral bioactivation and retention of BRB anthocyanins in healthy human
volunteers to help elucidate mechanisms attributable for these variations in responsiveness
(19). As BRB metabolizing enzymes are primarily distributed in the surface epithelia, OIN
lesional keratinocytes are well-positioned to benefit from BRB bioactivation (19). Also,
there is extensive inter-donor heterogeneity with regard to epithelial levels of enzymes
responsible for BRB bioactivation and local enteric recycling (19). It is therefore logical to
speculate that patients with higher levels of BRB bioactivation and local enteric recycling
enzymes would derive greater chemopreventive benefit due to sustained levels of BRB
chemopreventives at the OIN lesional site. A component of this current study was designed
to further investigate this BRB metabolism-therapeutic efficacy question.
The current study expanded upon our pilot study as it was multi-University based (Ohio
State, North Carolina at Chapel Hill (UNC) and Louisville), incorporated both a BRB
containing and a BRB-devoid (placebo) gel and doubled treatment time (3 months versus six
weeks). Therapeutic efficacies of BRB-containing and placebo gels (0.5 gm applied q.i.d.
for 3 months) were determined by their effects on: 1) clinical lesional size, 2) OIN
histopathologic grade, 3) LOH status at putative tumor suppressor gene loci associated with
OIN progression to OSCC [3p14 (FHIT), 9p21 (INK4a/ARF), 9p22 (IFNα) and 17p13
(p53)]. Pretreatment OIN biopsies were used to microscopically confirm a premalignant
diagnosis and provide baseline biomarkers. Additional protein profiling assays were
conducted to assess the contribution of differentiation and metabolic-local recycling
enzymes on BRB gel efficacy. Results from the current study confirm therapeutic efficacy is
attributable to the BRB constituents as only the BRB gel treated lesions showed significant
therapeutic responses as indicated by improvement in lesional size and histologic grade and
reduction of LOH events. In contrast, placebo-gel treated lesions significantly increased in




Freshly harvested black raspberries from Strums Berry Farm (Corbett, OR) were
immediately freeze-dried and ground into powder at Oregon Freeze Dry Inc (Albany, OR).
BRB powder was shipped on dry ice to JR Chemical, LLC (Milford, CT) for gel preparation
using Current Good Manufacturing Practices. The BRB gel composition used in this trial
was identical to our pilot study (14). The placebo formulation replaced 10% FBR with 10%
w/w sucrose and food colorants (FD&C Red #40 and FD&C Blue #1) to provide the
matching dark blue-black color. With the exception of sucrose and food colorants, the
placebo gel was identical to the 10% FBR gel. The 10% FBR-containing and placebo gels
are manufactured by JR Chemical LLC.
Covance Laboratories Inc. (Madison, WI) analyzed the BRB powder. Berry constituents
were found to closely replicate (≤ 15%) the component distributions in the pilot gel batch
(14). Gel stability and bioburden tests for both the BRB and placebo gels were conducted by
Bioscreen Testing Services, Inc. (Torrence CA) at 0, 1, 3, 6, 9, 12, 18 and 24 months, which
corresponded to the time frame for gel usage.
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Clinical Trial Inclusion/Exclusion Criteria
Investigational New Drug approval was obtained from the FDA (IND#109774). IRB
approvals were obtained from the Institutional Review Boards at all three participating
Universities i.e. Ohio State, University of North Carolina, Chapel Hill and Louisville (Trial
registration ID: NCT01192204). Forty adults (See Table 1) were consented for trial
participation. Inclusion criteria were microscopically confirmed premalignant oral epithelial
lesions, no use of tobacco products for six weeks prior and during the three month study and
no previous history of cancer (except for basal cell carcinoma of the skin). Participants were
screened prior to entrance into and during (10 to 12 day recall intervals) the trial for no
tobacco use compliance via unannounced saliva testing for nicotine (NicAlert™, JANT
Pharmacal Corporation, Encino, CA). Trial exclusion criteria were previous or current
history of non-basal cell cancer, use of tobacco products, and either a microscopic diagnosis
of no premalignant change or oral squamous cell carcinoma (OSCC) in the pretrial biopsy.
The National Cancer Institute common toxicity criteria version 4.0 was used. All
participants returned to clinic every 10 to 14 days for continued assessment. Used gel tubes
were returned and new gels were dispensed.
Histologic Grading Criteria
Formalin-fixed, paraffin-embedded biopsies were sectioned and stained with hematoxylin
and eosin. Photomicrographs were taken using an Olympus BX51 microscope (Olympus,
Japan) with 10x objective lens and a Nikon DS-Fi1 digital camera (Nikon, Japan) through
ImagePro 6.2 software (MediaCybernetics, Bethesda, MD). A 0–8 grade scale (0=normal
with or without hyperkeratosis, 1=atypia with crisply defined clinical margins, 2=mild
dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia, 5=moderate-severe dysplasia,
6=severe dysplasia, 7=carcinoma in-situ, 8=invasive SCC) was used to rank the light
microscopic diagnoses. A diagnosis of “hyperkeratosis” alone indicated a benign, reactive
change without evidence of premalignant potential. “Atypia” indicated architectural and
cytologic alterations that in the clinical setting of an adherent crisply defined white plaque
represent early premalignant change. To reduce subjectivity, two board-certified oral and
maxillofacial pathologists reached consensus before a final diagnosis was rendered (20). All
participating oral pathologists, surgeons and patients were blinded to the patients’ gel
assignments.
Assessment of Lesional Clinical Size—Clinical photographs of the participants’ OIN
lesions [pretreatment-time 0, week 1 (biopsy follow-up, baseline for subsequent
measurements), mid-study (6 weeks), and immediately prior to final biopsy] were taken with
a calibrated measuring device (Puritan, Guilford ME) placed parallel to the long axis of the
lesion. Acquired clinical images were analyzed using ImagePro 6.2 software (Media
Cybernetics, MD). Lesional sizes were normalized to square millimeters (mm2) according to
the following formula: lesional size mm2=pixels of lesional area×100/(pixels of 1 centimeter
unit on the calibration device in the same image2. The remaining lesional area after the
initial biopsy and prior to gel treatment was the pretreatment size. Posttreatment lesional
size was the residual lesional area after 3 months gel treatment and just prior to the final
biopsy.
Tissue microdissection and DNA isolation—Formalin-fixed, paraffin-embedded
biopsies were sectioned at 8µm thickness on PEN membrane slides (Carl Zeiss, Germany).
The entire oral epithelia and the corresponding histologically normal connective tissue were
independently captured from pre- and posttreatment biopsies using the PALM Microbeam
IV laser capture microdissection (LCM) system (Carl Zeiss, Germany) at The OSU Laser
Capture Molecular Core. QIAamp DNA Micro kit (QIAGEN, Valencia, CA) was use for
DNA extraction.
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PCR amplification and Detection of Allelic imbalance—Genomic DNA isolated
from the LCM samples was amplified using the predesigned primers with a 5’ fluorescent
label on the forward primer (Life Technologies, Grand Island, NY). The microsatellite
markers selected for LOH analyses and their corresponding loci and associated genes were:
3p14 [D3S1007(VHL), D3S1234 (FHIT)], 9p21 [D9S171, D9S1748(P16/CDKN2A),
D9S1751(P16)], 9p22 (IFNα), and 17p13 [D17S786 (P53) and TP53]. 20 µl PCR mixture
which contained5 µl of genomic DNA, 2 µl of primer mix (0.5 µM of each primer), 10µl of
AmpliTaq Gold 360 master mix (Life Technologies), and 3 µl of nuclease-free water was
amplified using a iCycler thermal cycler (Bio-Rad, Hercules, CA). PCR conditions were:
95°C for 5 min followed by 40 cycles of 95°C for 15 s, 59°C for 30 s, 72°C for 45 s, and a
final elongation step of 72°C for 7 min. Fragment analyses were performed at the OSU Plant
Microbe Genomics Facility using the Applied Biosystems 3730 sequence analyzer (Foster
City, CA). 1µl of PCR product DNA was added to 9µl HiDi (formamide; Applied
Biosystems, Inc.) and 0.2µl or 0.4µl (volume dependent upon DNA concentration)
GeneScan-500 LIZ Size Standard (Applied Biosystems, Inc.) for analysis. Both automatic
and manual (enabled editing) settings for allele identification (GeneMapper® v4.0, Applied
Biosystems) were used to analyzed electropherogram data. Peak intensities ≤ 50 RFUs were
excluded for being within background. Microsatellite marker peak patterns and allele sizes
were established from normal DNA (15). Connective tissue control samples with only one
allele were deemed “Not Interpretable” (NI). In several instances, the PCR amplification
products in the normal connective tissue for a particular patient/marker combination were
inadequate to allow LOH determination and were designated as Not Available (NA). LOH
determinations were made using a modification of the protocol established by Canzian et al.
(21) as described by Shumway et al. (15), using an increased level of stringency (>50%
reduction in peak intensity) to accept the presence of LOH (21). Baseline OINLOH status
was determined from the initial biopsy and then compared to LOH status in treated lesional
tissue.
Evaluation of differentiation and local enteric recycling enzymes and cornified
envelope precursor proteins by immunoblot analyses—Western immunoblotting
was conducted as previously described (19). Primary antibodies and dilutions were:
transglutaminase 1 (TGase 1, Abcam, ab27000 Cambridge MA, 1:400), loricrin (Abcam,
ab85679, 1 µg/ml, involucrin (Santa Cruz Biotechnology, Santa Cruz, CA, sc-21748, 1:200),
cytokeratin 10/13 (Santa Cruz, sc-70908,1:200), UDP-glucuronosyltransferase 1A (UGT1A,
Santa Cruz, sc25847,1 to 400), UDP glucose dehydrogenase (UDP-GlcDH, Santa Cruz,
sc137057,1:100), pan-cytokeratin (Santa Cruz, sc8018, 1:200). Secondary antibodies were:
goat anti-mouse IgG-HRP (Santa Cruz), goat anti-rabbit IgG-HRP (Dako, Carpinteria, CA).
Positive controls for TGase1 (TGase 293T lysate), involucrin (CCD-1064 cell lysate),
loricrin (Hep G2 cell lysate), cytokeratin 10/13 (A-431 whole cell lysate), pancytokeratin
(A-431 whole cell lysate),UGT1A (Hep G2 cell lysate), UDP-GlcDH (Hep G2 cell lysate)
were all purchased from Santa Cruz. The Kodak 1D3 image analysis software (Kodak,
Rochester, NY) was used for densitometery analyses. Results were normalized relative to
endogenous pancytokeratin expression because: 1) the enzymes either exclusively
(transglutaminase 1) or predominantly reside in surface epithelia (19), 2) cornified envelope
proteins are epithelial, and 3) proteins normalized relative to epithelial as opposed to
epithelia + connective tissue content of the biopsies. See Supplemental Table S1 for the
physiological functions of these selected proteins.
Determination of the overall therapeutic responsiveness—A responsiveness score
that incorporated extent of changes in lesional size, histologic grade and LOH was
determined for every trial participant. A -3 to 3 responsiveness score scale of lesional size
was developed to reflect the extent of change inlesional size. i.e. ≥75% decrease=3, 50%–
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74% decrease=2, 25–49% decrease=1, 0–24% decrease or increase=0, 25–49% increase=
−1, 50% –74% increase= −2, and ≥75% increase= −3. The cumulative responsiveness score
was then calculated according to the following formula: Cumulative responsiveness score=
Lesional size responsiveness score + Histologic grade responsiveness score (Pretreatment
grade – Posttreatment grade) + LOH responsiveness score (Pretreatment events –
Posttreatment events). Finally, overall therapeutic responsiveness was categorized in
accordance with cumulative scores as follows: 1) High responder≥4, 2) Intermediate
responder=3, 3) Low responder=1 or 2, 4) Non-responder≤0.
Statistical Analyses—Two-tailed Mann Whitney U tests were employed to compare
pretreatment baseline parameters i.e. size, histologic grade and LOH events in the BRB and
placebo gel cohorts. A Wilcoxon Matched Pairs Signed Rank Test was used to compare the
pre and post-treatment histologic grades, clinical lesional sizes and LOH events. Cumulative
treatment responses (effects on lesional size, histologic grade and LOH events) were
evaluated by two-tailed unpaired t test. A Fisher’s Exact Test was used to compare
distribution of responsiveness between the BRB and placebo gel treatments. Associations
between two therapeutic evaluative parameters were determined by a Spearman Rank
Correlation. Relationships among size, histologic grade and LOH used multiple regression
analysis. Normality of data determined the use of parametric versus nonparametric analyses.
Results
Patient Demographics and Comparable Pretreatment Baseline Parameters
Forty patients participated in this study. Participants’ ages ranged from 44 to 77 (mean
62.2±1.8) and 32 to 78 (mean 57.7±2.9) in the BRB and placebo gel cohorts, respectively. A
majority of the patients never smoked (55% in BRB and 67% placebo gels) and tongue was
the most common OIN site in both groups. The gender distribution in the BRB gel cohort
was 78.2% (15 women) and 31.8% (7 men) whereas the placebo group was evenly
distributed (50% each, 9 women, 9 men) (Table 1). Thirty of the participants had OIN
lesions (16 in BRB-72.7% and 14 in the placebo-77.7%) that were recalcitrant to surgery,
and had recurred multiple times (2 to 8) at the same site prior to trial participation. Twelve
BRB (54.5%) and 3 placebo gel (16.7%) participants had a history of multiple premalignant
oral epithelial lesions dispersed throughout their mouth, consistent with a diagnosis of
proliferative verrucous leukoplakia (Table 1). No histopathologic evidence of concurrent
human papillomavirus infection e.g. koilocytic change in lesional epithelial cells was
observed in any of the pre or post treatment lesional tissue biopsies.
Patients in the BRB and placebo gel cohorts had comparable pretreatment ages, clinical
lesional sizes, histologic grades, and LOH status. BRB gel patients’ pretreatment lesional
sizes (70.95±15.66 mm2n=21) were comparable to Placebo patients’ lesions (61.63±14.39
mm2n=17) (Fig. 1C). One patient in both groups (subjects A4 and P11) had diffuse
confluent adherent white plaques that prohibited delineation of a discreetly measurable
lesional site. Comparable pretreatment histologic grades were present in both groups
[pretreatment BRB group (2.36±0.35, n=22) &pretreatment Placebo group (2.83±0.34,
n=18), see Fig. 2C]. Pretreatment LOH events (per patient) for all eight markers were also
comparable between BRB gel group (1.36±0.28, n=22) and Placebo gel group (1.06±0.24,
n=18) (Fig. 3C). Forty three percent of BRB and 26% of placebo pretreatment lesions
demonstrated 9p associated allelic imbalance. The overall pretreatment LOH indices were
27.8% and 21.8%, in the BRB and placebo gels, respectively.
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No deleterious effects were observed in either the BRB gel or placebo gel cohorts and
compliance was excellent
While topical application of a gel could result in deleterious effects e.g. contact mucositis or
superimposed Candidiasis, no participant experienced any treatment-associated
complications. Furthermore, as determined by the minimal residual gel in the returned gel
tubes (>95% dose used), patient compliance was high.
BRB gel significantly decreased OIN lesional clinical size
Following 3 months of BRB gel application, 16 of the 21 BRB treated lesions decreased in
size (p=0.0019) for an average overall size decrease of 26%. In contrast, 17 of the 19
placebo gel treated lesions increased in clinical lesional size (p=0.0395) with an average
increase of 18%. (See Table 1Fig. 1 A, B and C). While none of the placebo gel patients
experienced complete lesional regression, two BRB gel patients had 100% lesional
resolution. These individuals’ mucosa returned to a clinically (and histologically) normal
and healthy appearance (Fig. 1D).
OIN histologic grade was also significantly reduced by BRB gel application while placebo
gel had no significant effect
Comparison of the histologic grade of the pretreatment versus post-treatment lesional tissue
biopsies demonstrated that application of the BRB gel resulted in a statistical decrease in
histopathologic grade (p=0.0488) while placebo gel application did not significantly impact
histopathologic grade (p=0.4961) (Table 1 and Fig. 2).
Topical application of BRB gel significantly reduced allelic imbalance in OIN lesions
BRB gel treated lesions demonstrated a statistically significant reduction in LOH events at
all 9p loci relative to pretreatment parameters p=0.016, n=22. With regard to all loci
evaluated, BRB gel treatment significantly reduced overall LOH events, p=0.002, n=22. In
contrast, placebo gel application resulted in comparable 9p pre and post-treatment LOH
status and did not significantly reduce overall LOH events (Table 1 and Fig. 3).
Collective assessment of extent of treatment effects on lesional size, histopathologic
grade and LOH events reveals highly BRB-responsive cohort
Cumulative scores, which reflected the extent of gel application effect on lesional size,
histologic grade and LOH indices, were assigned for every trial participant (Table 1 and Fig.
4A and B). BRB gel participants had a statistically significant (p=0.004) higher scores,
indicative of greater therapeutic effects (Fig. 4C). Nine of the 22 BRB gel participants’
(41%) OIN lesions achieved high to intermediate responsiveness whereas all of the placebo
patients were either low (55%) or nonresponders (no therapeutic effects) (Table 1Fig. 4D).
Correlative analyses showed a significant association between improvement in histologic
grade and reduction in lesional size (p=0.009) in the BRB gel treatment cohort (Fig. 4E).
Multivariate analyses of the BRB gel OIN data also revealed a significant relationship
among treatment effects on lesional size (identified as outcome), histologic grade and LOH
indices (p=0.0001). Consistent with the Spearman Correlation findings, histologic grade
made the largest contribution to the multivariate significance. No linear associations or
multivariate relationships were detected in the placebo gel data.
Baseline levels of differentiation and enteric recycling proteins may help identify BRB-
responsive OIN lesions
Samples for protein assessment were only available from the larger OIN lesions, resulting in
a reduced data set. Baseline intra BRB gel cohort analyses reveals a trend for higher lesional
intraepithelial levels of differentiation-associated proteins (TGase 1, involucrin 140 kDa,
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involucrin 68 kDa, loricrin and cytokeratin 10/13) and enteric recycling enzymes (UGT1A
and UDP-Glc DH) in those OIN lesions which responded in a therapeutic fashion to BRB
gel application (Fig. 5A and B). No significant associations were identified in the placebo
gel cohort. (Fig. 5C and D). Finally, the most BRB gel responsive OIN lesions had the
highest pretreatment levels of differentiation-associated proteins (Supplemental Figure 1).
Longer-term follow-up reveals OIN lesional recurrence in both cohorts
Thirty eight of the 40 trial patients were available for the requisite three month post trial
evaluation; one patient each was lost to follow up in the BRB and placebo gel cohorts. Three
months after trial cessation, 6 of 22 BRB and 7 of 17 placebo patients had visible evidence
of lesional recurrence at the former treatment sites (Table 1). Only one patient (P6) lesion
had a clinically significant lesional recurrence that merited biopsy scheduling at the 3 month
recall.
Patients were then returned to their previous oral health care providers for subsequent care.
As many of these patients are treated by oral maxillofacial surgeons who use the pathology
biopsy services at the trial institutions, longer term follow-up (4 to 31 months post final
study biopsy) was available for many trial participants (See Supplemental Table S2). Longer
term post-study biopsies were received from 8of the 22 BRB gel and 6 of the 18 placebo gel
cohort patients. Two BRB gel cohort patients’ lesions (25%) regressed to non-premalignant
states, 4 biopsies remained stable (50%), and 2 lesions progressed (Supplemental Table S2).
One of these progressive patients underwent progression of two histologic grades whereas
another lesion returned to its pretrial histopathologic grade. Three of the six placebo gel
patients’ lesions remained stable, three lesions progressed. Two of the three progressive
lesions from the placebo gel cohort increased one histologic grade while the third
individual’s lesion (P11) progressed from atypia (pretreatment) to moderate dyplasia (post
placebo gel application) to OSCC in the 12 months post trial (Supplemental Table S2).
Discussion
Topical application of a 10% BRB gel resulted in significant reduction in size, histologic
grade and LOH events in OIN lesions. The absence of comparable results following placebo
gel application strongly supports BRB’s chemopreventive impact and dispels other
contributions such as topical stimulation during gel application or hydrogel constituents.
Much of BRB’s chemopreventive effect is derived from the primary phenolic compounds
i.e. anthocyanins (16, 22, 23). BRB anthocyanins are redox active compounds which possess
both redox scavenging and redox generating properties (24, 25). Accordingly, anthocyanins
can quench reactive oxygen species (ROS)-mediated signaling, reduce adverse DNA-ROS
and/or protein-ROS interactions, and inhibit lipid peroxidation (26). Such activities can
ultimately suppress inappropriately sustained proliferation and limit DNA and protein
perturbations (23, 27). As bulky sugar moieties reduce ROS scavenging capacity, epithelial
and oral microflora initiated deglycosylation generates superior antioxidants i.e. the labile
aglycones or the more stable protocatechuic acid (28, 29). Anthocyanins also generate ROS
(25). At alkalotic pH levels, anthocyanins/anthocyanidins are speculated to form quinones,
release superoxide and H2O2, and in the presence of oxidized transition metals, generate the
highly mutagenic hydroxyl radical (25). Proximity to anthocyanin-generated superoxide
anions and quinone reduction can induce mitochondrial uncoupling, initiate mitochondrial
failure and trigger apoptosis (30, 31). Provided the complexity of factors that can modulate
BRB chemopreventive impact e.g. metabolism and recycling, pH, presence of reducing
equivalents and keratinocyte levels of cytoprotective enzymes, the variability in BRB gel
responsiveness observed in this study is understandable (14, 15, 19 and 26).
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Lesion regression is one of the most consistently used therapeutic efficacy parameter in
human clinical trials (10–12). Placebo gel application resulted in an overall size increase in
70.6% lesions, a finding that is consistent with the proliferative potential of nontreated
premalignant oral lesions (32). In contrast, BRB gel application reduced size in 76.2% of
OIN lesions. These data compare favorably to previous OIN studies (data expressed as % of
lesions which showed a decrease in size) which evaluated: Trial 1) 13cis retinoic acid [0.5
mg/kg P.O.×1 year followed by 0.25 mg/kg P.O.×2 years (48.1%)], or β-carotene + retinyl
palmitate [50 mg/d β-carotene + 25,000U/d retinyl palmitate for 3 years (42.9%)], or retinyl
palmitate [25,000U/d for long term follow up (20.0%)](10), Trial 2) Celecoxib (100
mg-41.2%, 200 mg-20%, b.i.d. dosing×3 months) (12), and Trial 3) green tea extract
[combined green tea extract doses 50%, n=28 (500 mg/m2750 mg/m21000 mg/m2all doses
administered t.i.d.×3 months)](11). The corresponding placebo data showed 33% and 18.2%
of lesions with size reduction in the Celecoxib and green tea extracts, respectively (11, 12).
The cis-retinoic acid study did not include a placebo group. Adverse effects accompanied
the systemic administration and included Grade III toxicity with use of 13cis retinoic acid
and induction of caffeine-attributable insomnia and anxiety with the higher green tea extract
doses (10, 11).
Following BRB gel application 41% of participants achieved a decrease in lesional grade,
4.5% a lesional grade increase and 54.5% retained stable OIN histology. While the 41%
grade decrease is identical to our pilot BRB gel trial (14), the percentage of OIN lesions that
histologically progressed are 5 fold lower in the current study; findings that likely reflect the
doubled treatment time of the current trial (14). A range of histologic responsiveness has
been observed in other OIN clinical trials (10–13). The “most responsive” group (13-cis
retinoic acid) in the combination 13 cis-retinoic acid, β-carotene and retinyl palmitate trial
demonstrated a 30% histologic reduction (10). In the green tea extract study, 33% (3 of 9)
obtained histologic regression in the most responsive but toxicity-associated highest dosing
group (1,000 mg/m2 t.i.d.), with an overall, a 21.4% rate of histologic regression (6 of 28)
(11). The Celecoxib trial did not include histopathologic assessment (12). Recently, the
effects of combined administration of Celecoxib (400 mg bid) with escalating doses (50, 75,
100 mg q.d.) of the EGFR inhibitor Erlotinib were assessed on premalignant oral and
laryngeal lesions (13). Comparison of baseline histology to final biopsies (obtained at 3, 6 or
12 months) in the 7 evaluable patients showed 43% complete regression (3/7, one laryngeal,
two oral lesions), 14% (1/7) partial regression, 29% (2/7) stable disease, and 14%
progression (1/7) (13). No placebo group was included (13). Complementary biomarker
studies demonstrated significant reduction of EGFR and p-ERK in biopsies that showed
histologic improvement (13). Erlotinib dose escalation was accompanied by toxicities
including oral mucositis, rash, anemia, sepsis, and elevated liver enzymes; effects that the
authors acknowledged as unfavorable for primary chemoprevention (13). Because oral
dysplastic lesions have been shown to be less treatment-responsive than oropharyngeal
lesions (33), separate reporting of oral and laryngeal lesions appears warranted in more
definitive studies (33).
Due to the effects of first pass metabolism and the need for the agent to perfuse from the
connective tissue papilla to the avascular epithelia, bioavailability is often challenging for
systemically administered OIN chemopreventives (34). Attempts to address the
bioavailability challenge by dose escalation are often accompanied by toxicity (11, 13).
Furthermore, it is interesting that neither this recent pharmacokinetic study (13) nor any of
the previously cited OIN trials determined levels of parent compound(s) and/or metabolites
achieved at the treatment site (10–12). Prior to conducting our pilot clinical trial we
established that topical BRB gel application provides a pharmacologic advantage at human
oral mucosa (35).
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LOH-mediated inactivation of one of the two alleles of tumor suppressor genes followed by
silencing of the second allele via promoter methylation or point mutation is a putative and
probable tumorigenic mechanism (36, 37). Clinical data, which demonstrate a higher risk of
malignant transformation in OIN lesions that harbor LOH at tumor suppressor gene loci,
support this premise (15, 38). Pretreatment LOH events detected in the current study were
lower than those detected in either our pilot trial and in two investigations conducted by
Mao et al. (39, 40). These variations likely reflect differences in baseline lesion histology,
LOH analytical methods and microsatellite markers evaluated (15, 39, 40). Consistent with
previous investigations (15, 37, 39, 40), allelic imbalances in this current study were highest
at the 9 p loci. BRB gel treatment significantly reduced allelic imbalances whereas placebo
gel did not significantly affect LOH status. To our knowledge, our pilot BRB pilot gel trial
(15) and this current study are the only OIN chemoprevention trials to demonstrate a
significant reduction in LOH occurrence. We speculate these data reflect removal of LOH
harboring keratinocytes from the proliferative pool via BRB-mediated induction of
apoptosis and/or differentiation, as previously demonstrated by in vitro studies (31).
Although preliminary, our protein profiling data suggest that BRB gel responsiveness may
be associated with lesional keratinocytes’ differentiation and local enteric recycling
enzymatic capacities. Provided additional studies substantiate these findings, baseline
protein levels could be used in a “personalized medicine approach”toidentify OIN lesions
with a high probability of responsiveness. Notably, the highest pretreatment levels of
differentiation-associated proteins were detected in the most responsive BRB gel cohort.
The observed post treatment lesional recurrences were not surprising, particularly because
over 70% of the patients enrolled in this trial had histories of multiple recurrences of the
OIN lesion selected for treatment. These recurrences, which are consistent with retention of
genetically altered, long-lived stem cells at the lesional site, emphasize the need for
effective, non-toxic, long-term chemoprevention strategies.
This study shares shortcomings with other OIN trials. First is the dynamic nature of OIN
lesions. OIN lesions with a homogenous clinical appearance can still demonstrate molecular
and/or histologic heterogeneity (41). Also, as a result of ongoing epithelial turnover baseline
to post treatment biopsies are not direct comparisons. Instead, these measurements assess the
effects of treatment on transient amplifying and more mature lesional keratinocytes over
time. Furthermore, low patient numbers precluded our ability to determine whether or not
clinical site or baseline histologic grade affected therapeutic responsiveness. Another
common clinical trial challenge is the inter-patient variation in responsiveness. Our data
imply these results reflect differences in local tissue absorption and the extensive variability
in human oral mucosal metabolic bioactivation, local enteric recycling and keratinocyte
differentiation-associated enzymes (19).
A recent editorial by a well-respected oral cancer chemoprevention researcher helps to place
our results in perspective (42). The presence of LOH at specific chromosomal loci (3p and
9p) was acknowledged as the most consistent molecular marker of oral cancer risk (38, 41).
Also discussed was the in ability to identify a standard systemic treatment protocol despite
numerous, costly OIN chemoprevention clinical trials (42). In this context, BRB gel
outcomes, which include significant reduction in OIN LOH events, lesional size and
histologic grade without adverse effects, are favorable.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Oral squamous cell carcinoma (OSCC), which arises from its premalignant precursor oral
intraepithelial neoplasia (OIN), is a world-wide health problem. While not all OIN
lesions will transform, approximately 30% of the higher-grade lesions progress to OSCC.
Furthermore, OIN lesions often recur despite complete surgical excision. Numerous
chemoprevention studies have therefore attempted to induce regression in or prevent
progression of OIN lesions. Modest success and dose-limiting toxicities were often the
outcomes of these clinical trials. The majority of previous OIN clinical studies relied
upon systemic chemopreventive agent administration. In contrast, this study assessed the
effects of a food-based (freeze-dried black raspberries) bioadhesive gel on OIN lesions.
Our results, which demonstrate BRB gel significantly reduces loss of heterozygosity,
lesional size and histologic grade in OIN lesions without any toxicities combined the
absence of such effects in the placebo gel cohort, are favorable.
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Effect of gel treatment on lesional size. Histograms A. (BRB gel) and B.(Placebo gel) depict
pre- and post-treatment lesional size (mm2) of individual subjects’ OIN lesions. The lesional
sizes of subject A4 in BRB group and subject P11 in Placebo group were not included as the
extensive distribution and confluent nature of their dysplastic lesions made accurate
measurement impossible. C. The mean pretreatment lesional sizes of both groups were
statistically comparable. Intragroup pre/post lesional sizes significantly decreased in BRB
gel treatment group while significantly increased in Placebo group. D. Intergroup
comparison reviewed a significant difference between BRB and Placebo groups. E. This
clinical photograph of subject A6 was taken prior to the initial biopsy of the crisply defined
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rhomboid white plaque close to commissure. The area of the residual lesion remained after
initial biopsy was measured as the pretreatment biopsy size. F. Clinical photograph at the
same site after 3 months BRB gel treatment and immediately prior to the final biopsy. The
remaining lesion had completely regressed and the buccal mucosa at the treatment site had a
normal clinical appearance.
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Effect of gel treatment on histologic grade. Histograms A. (BRB gel) and B. (Placebo gel)
depict pre- and post-treatment histologic grades of individual subjects’ OIN lesions using
the following scale: 0=normal, 1=atypia, 2=mild dysplasia, 3=mild to moderate dysplasia,
4=moderate dysplasia, 5=moderate to severe dysplasia, 6=severe dysplasia. None of the pre-
and post- treatment specimens was diagnosed as carcinoma in situ (7) or OSCC (8). C. The
baseline histologic grades of both pretreatment groups were statistically comparable.
Intragroup pre/post histologic grades significantly decreased in BRB gel treatment group
while changes in Placebo group were statistically insignificant. D. Categorization of subjects
as per histopathologic responsiveness. E. and F. Photomicrographs of pre- and post-
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treatment specimens of subject A6 (10x) demonstrated complete histopathologic regression
from mild dysplasia (E, pretreatment) to normal epithelium (F, posttreatment). G. and H.
pre- and post- treatment photomicrographs of subject A7 (10x) showed partial regression
from severe dysplasia (G, pretreatment) to mild to moderate dysplasia (H, posttreatment).
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Effect of gel treatment on loss of heterozygosity (LOH). A. and B. pre- and post-treatment
detected LOH events of individual subjects in BRB gel and Placebo gel groups, respectively.
C. Intragroup and intergroup statistical analyses. Mean LOH events significantly decreased
in BRB gel treatment group while changes in Placebo group were statistically insignificant.
The baseline LOH events of both pretreatment groups were statistically comparable. D.
classification of subjects as per treatment effects on LOH events. E. and F. Representative
genotyping data depict an LOH event occurred on marker D9S171 in subject A19’s
pretreatment samples [loss of one allele (al 154) in the epithelium tissue (E), compared to
the two alleles (al 154 and al 162) in the patient’s matched normal connective tissue (F)]. G.
Mallery et al. Page 19













and H. The lost allele (al 154) of D9S171 was recovered in the epithelial tissue (G) of the
same patient after 3 months of BRB gel treatment, and the ratio of peak heights in
epithelium (G) was comparable to the connective tissue sample (H).
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Overall therapeutic responsiveness. A. and B. cumulative responsiveness score of individual
subjects in BRB (A) and Placebo (B) groups. The cumulative responsiveness score is
defined as the sum of lesional size score (−3 to 3 as per the percent quartile of pre-/post-
lesional size changes i.e. 75–100% reduction=3, 50–74% reduction=2, 25–49% reduction=1,
24–0% reduction=0, 0–24% increase=0, 25–49% increase= −1, 50–74% increase= −2, >
75% increase= −3), histologic grade score (pretreatment histologic grade – posttreatment
histologic grade) and LOH score (pretreatment LOH events – posttreatment LOH events). C.
Comparison of the mean cumulative responsiveness scores between BRB and Placebo
groups. D, Categorization of subjects according to their cumulative responsiveness score,
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where high responder ≥4, intermediate responder=3, low responder=2 or 1, and non-
responder ≤0. E. A significant correlation was demonstrated between BRB gel treatment
effects on histologic effects and lesional size. No comparable correlation was detected in the
placebo gel group.
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Densitometry analyses of Protein Immunoprecipitation studies. Five proteins associated with
keratinocyte terminal differentiation (TGase 1, high molecular weight involucrin, low
molecular weight involucrin, loricrin, cytokeratin 10/13) and two with BRB metabolism
(UDP-Glc dehydrogenase and UGT1A) were evaluated in pre- and post- treatment biopsy
samples of those lesions that had adequate tissue. All densitometry results were normalized
to the percentage of sample-matched pancytokeratin level, which reflected the proportion of
epithelium tissue in each sample. Previous studies have confirmed the epithelial distribution
of UDP-Glc dehydrogenase and UGT1(19). Responder and non-responder were defined
according to the cumulative responsiveness score (responder≥1, non-responder ≤0). A. and
B. pre- and post- treatment protein levels in BRB group. Responders demonstrated a trend of
possessing higher level of associated proteins relative to the non-responders. C and D, pre-
and post- treatment protein levels in Placebo group. No statistical significance was
identified.
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